Skip to main content
PCSA
NASDAQ Life Sciences

Chief Development Officer Transitions to Part-Time Role, No Longer Executive Officer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.7
Mkt Cap
$7.182M
52W Low
$1.76
52W High
$19.635
52W Position info
53% above low
Off High info
86% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

PCSA sits 53% above its 52-week low of $1.76 on light trading volume (0.2× avg).

Summary

Processa Pharmaceuticals' Chief Development and Regulatory Officer, Dr. Sian Bigora, is transitioning to a part-time role and will no longer be considered an executive officer.


Key Events · Executive and Board Changes · PCSA

  • Executive Role Transition

    Dr. Sian Bigora, Chief Development and Regulatory Officer, will transition from a full-time executive officer to a part-time employee role effective May 1, 2026, as part of her planned retirement.

  • Loss of Executive Officer Status

    Dr. Bigora will no longer be designated as an "executive officer" for Section 16 purposes, though she will retain her title and continue to provide services in a reduced capacity.

  • Employment Agreement Change

    Her existing employment agreement will terminate and be replaced by a new part-time arrangement, while her previously granted equity awards and bonus eligibility remain.


Analysis · PCSA · Life Sciences

This filing reports a planned transition for Dr. Sian Bigora, the Chief Development and Regulatory Officer, moving from a full-time executive role to a part-time employee position. While she retains her title and continues to provide services, her designation as an "executive officer" for Section 16 purposes will cease. For a micro-cap pharmaceutical company, changes in the full-time commitment of a key development and regulatory officer can be a notable event, potentially impacting the pace or strategic direction of drug development, even if planned.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCSA was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $1.76 to $19.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 05, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.85
Real-time Price: $1.90 info
Change: +$0.050 (+3%) info
Market Cap: $5.317M info
PCSA
Oct 29, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.90 info
Change: -$0.050 (-3%) info
Market Cap: $5.317M info
PCSA
Oct 29, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.90 info
Change: +$0.010 (+0.53%) info
Market Cap: $5.317M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.90 info
Change: +$0.430 (+29%) info
Market Cap: $5.317M info
PCSA
Oct 09, 2026, 4:02 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.90 info
Change: +$0.430 (+29%) info
Market Cap: $5.317M info